MREO Mereo BioPharma Group plc

Nasdaq mereobiopharma.com


$ 1.79 $ -0.06 (-3.26 %)    

Thursday, 13-Nov-2025 15:59:54 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 1.78
$ 1.82
$ 1.76 x 40
$ 1.97 x 5,000
-- - --
$ 1.47 - $ 4.14
1,187,535
na
283.25M
$ 0.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-26-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-mereo-biopharma-group-raises-price-target-to-8

JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price targe...

 mereo-biopharma-group-q2-eps-002-misses-001-estimate-sales-500000k

Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate ...

 ultragenyx-represents-intriguing-buying-opportunity-despite-recent-setbacks

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by ...

 ultragenyx-mereo-shares-dive-as-brittle-bone-disease-drug-misses-early-win

Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected ...

 needham-maintains-buy-on-mereo-biopharma-group-lowers-price-target-to-5

Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $7 to $5.

Core News & Articles

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO), today announced that the randomized, ...

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-7-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $7 price target.

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-7-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $7 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION